
Quarterly report 2023-Q1
added 05-11-2023
Spectrum Pharmaceuticals Net Debt 2011-2026 | SPPI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.9 M | -85.8 M | -44.5 M | -60.4 M | -157 M | -189 M | -60.9 M | -37.9 M | -30.3 M | -61.4 M | -61.4 M | -121 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.9 M | -189 M | -76.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
59.5 B | $ 209.63 | -0.71 % | $ 371 B | ||
|
Verastem
VSTM
|
-36.9 M | $ 4.99 | -5.77 % | $ 346 M | ||
|
VistaGen Therapeutics
VTGN
|
-65.6 M | $ 0.57 | -5.85 % | $ 17.6 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Voyager Therapeutics
VYGR
|
-28.8 M | $ 3.96 | -4.24 % | $ 232 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
65 M | $ 12.36 | -11.46 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
-584 M | $ 6.39 | 3.06 % | $ 1.08 B | ||
|
Xenetic Biosciences
XBIO
|
-11.5 M | $ 2.78 | -0.71 % | $ 4.73 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
XBiotech
XBIT
|
-237 M | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
-134 M | $ 54.44 | -1.96 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
116 M | $ 5.41 | -2.87 % | $ 868 M | ||
|
X4 Pharmaceuticals
XFOR
|
-141 M | $ 4.07 | -5.57 % | $ 172 M | ||
|
Xencor
XNCR
|
25.7 M | $ 11.4 | -7.43 % | $ 846 M | ||
|
XOMA Corporation
XOMA
|
16 M | $ 29.93 | -1.97 % | $ 362 M | ||
|
22nd Century Group
XXII
|
-6.27 M | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-9.78 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-7.29 M | $ 1.06 | -2.75 % | $ 21.7 M | ||
|
Enochian Biosciences
ENOB
|
645 K | - | - | $ 40.5 M |